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Available online xxxxPurpose: The goal of the present study was to determine the efficacy of temozolomide (TEM) and pazopanib (PAZ) com-
bined with FOLFOX (oxaliplatin, leucovorin and 5-fluorouracil) on a colorectal cancer patient-derived orthotopic xeno-
graft (PDOX) mouse model. Materials and Methods: A colorectal cancer tumor from a patient previously established in
non-transgenic nude mice was implanted subcutaneously in transgenic green fluorescence protein (GFP)-expressing
nude mice in order to label the tumor stromal cells with GFP. Then labeled tumors were orthotopically implanted into
the cecum of nude mice. Mice were randomized into four groups: Group 1, untreated control; group 2, TEM + PAZ;
group 3, FOLFOX; group 4, TEM+ PAZ plus FOLFOX. Tumor width, length, and mouse body weight were measured
weekly. The Fluor Vivo imaging System was used to image the GFP-lableled tumor stromal cells in vivo. H&E staining
and immunohistochemical staining were used for histological analysis. Results: All three treatments inhibited tumor
growth as compared to the untreated control group. The combination of TEM+PAZ+FOLFOX regressed tumor growth
significantly more effectively than TEM+ PAZ or FOLFOX. Only the combination of TEM + PAZ + FOLFOX group
caused a decrease in bodyweight. PAZ suppressed lymph vessels density in the colorectal cancer PDOXmousemodel sug-
gesting inhibition of lymphangiogenesis. Conclusion:Our results suggest that the combination of TEM+PAZ+FOLFOX
has clinical potential for colorectal cancer patient.Introduction
Surgical resection, radiotherapy and adjuvant chemotherapy are themain
treatments for colorectal cancer [1]. Currently, oxaliplatin (OXA) in combina-
tionwith 5-fluorouracil (5-FU) and leucovorin (LV), termed FOLFOX, showed
response rates of more than 50% and increased the survival rate of colorectal
cancer [2, 3]. The FOLFOX chemotherapy regimen has become first-line pro-
tocol for adjuvant treatment of colorectal cancer [4]. However, colon-cancer
patients develop tumor recurrence [5–7]. Therefore, more effective therapy
strategies are needed for advanced colorectal cancer.
To accomplish this goal, we have developed the patient-derived
orthotopic xenograft (PDOX) nude mouse model for all cancer types
[8–17]. To improve efficacy of chemotherapy on colorectal cancer patient,Cancer, Inc, 7917 Ostrow St, San
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were developed [17–24].
Pazopanib (PAZ) is an orally-available, multi-targeted targeted tyrosine
kinase inhibitor of vascular endothelial growth factor receptors (VEGFRs),
including VEGFR-1, VEGFR-2 and VEGFR-3, to which it has high affinity
[25]. PAZ can inhibit the receptors of platelet-derived growth factor
(PDGF), fibroblast growth factor (FGF) receptor and c-kit [26–28].
Bennouna et al. [29] reported that PAZ could be safely given in combina-
tion with irinotecan to patients with advanced colorectal cancer. Fu et al.
[30] also showed that PAZ could be safe for patients with metastasis colo-
rectal cancer in a Phase I study [30]. Zhang et al. [31] reported that PAZ di-
rectly inhibited colon cancer cells in vitro.
Temozolomide (TEM) is an oral alkylating agentwith a broad spectrumof
antitumor activity [32]. TEM targetsmethylation and induces apoptosis [32].
TEM has been used in the treatment of patients with glioblastoma [33, 34],
metastatis melanoma [35] and pancreatic neuroendocrine tumors [36].
However, the use of TEM is controversial in colorectal cancer [37, 38].
In the present study, we identified a therapeutics strategy with the com-
bination of TEM + PAZ + FOLFOX in a colorectal cancer PDOX nude-
mouse model.
Figure 1. Establishment of an imageable patient-derived orthotopic xenograft
(PDOX) model of colon cancer and the drug treatment schema. (A) Schematic
illustration of subcutaneous and surgical orthotopic implantation (SOI) to
establish an imageable PDOX (iPDOX) model of human colorectal cancer.
(B) Treatment regimen and quantitative drug efficacy. Treatment protocol. G1:
untreated control; G2: treated with TEM + PAZ (TEM 25 mg/kg, oral.; PAZ 50
mg/kg, oral, daily for 3 weeks); G3: treated with FOLFOX (OXA 6 mg/kg, ip., LV
90 mg/kg, ip.; 5-FU 50 mg/kg, ip.; weekly for 2 weeks); G4: treated with TEM
+ PAZ + FOLFOX(TEM 25 mg/kg, oral.; PAZ 50 mg/kg, oral, daily for 3 weeks;
OXA 6 mg/kg, ip., LV 90 mg/kg, ip.; 5-FU 50 mg/kg, ip.; weekly for 2 weeks). All
treated mice were sacrificed on the endpoint day, and tumors were resected for
further histological accession.
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Mice
In this study, transgenic green fluorescence protein (GFP)-expressing
and non-transgenic athymic nu/nu mice, 4 to 6 weeks old, were used. All
mice were obtained from AntiCancer Inc. (San Diego, CA, USA). Mouse
housing, feeding, and surgical procedureswere performed as previously de-
scribed [16, 39, 40]. Themicewere observed on a daily basis and humanely
sacrificed as previously described [40]. All animal experiments were car-
ried out in accordance with AntiCancer Inc. Institutional Animal Care and
Use Committee (IACUC)-protocol specifically approved for this study, and
in accordance with the principles and procedures outlined in the National
Institutes of Health Guidelines for care andUse of Animals under Assurance
Number A3873–1 [15] as previously described [40].
Patient-Derived Tumor
The primary colorectal cancer tumor samples were previously obtained
in the Division of Surgical Oncology, University of California, San Diego
(UCSD) from a patient who did not receive any chemotherapy or radiother-
apy before surgery [22, 24]. Informed patient consent and Institutional Re-
view Board (IRB) approval was obtained before surgery. Using the surgical
orthotopic implantation (SOI) technique a colorectal cancer PDOX mouse
model was established, as previously reported [41].
Establishment of an Imageable Colorectal Cancer PDOX Nude Mouse Model
Colorectal cancer tissues were cut into 5 mm3 fragments and seeded
subcutaneously in nude mice. The colorectal cancer tumors grown in
nude mice were then harvested, cut into 5 mm3 fragments, and implanted
subcutaneously nude mice expressing green fluorescence protein [42,
43]. After two passages in GFP-expressing nude mice, colorectal cancer tu-
mors containing GFP-expressing stromal cells, were harvested and cut into
5 mm3 fragments [44]. After that non-GFP-expressing nude mice were
anesthetized with ketamine-mixed drug (20 mg/kg ketamine, 15.2 mg/kg
xylazine, and 0.48 mg/kg acepromazine maleate), and an approximately
1 cm skin incision was made at the middle of the abdomen. A 5 mm3
tumor fragment was sutured on the cecum. The incision was closed using
6–0 nylon sutures as previously described [41]. The schematic diagram to
establish a colorectal cancer PDOX model is shown in Figure 1A.
Treatment Study Design in the Colorectal Cancer PDOX Nude Mouse Model
Six weeks after orthotopic implantation of colorectal cancer-GFP tu-
mors, the abdomen of the PDOX mice was opened to measure tumor
growth. The PDOX mice were randomized into 4 groups (5 mice/per treat-
ment group) by measuring tumor size: Group 1 (G1), control group (no
treatment); Group 2 (G2), TEM + PAZ (TEM 25 mg/kg, oral; PAZ 50
mg/kg, oral, daily for 3 weeks); Group 3 (G3), FOLFOX (OXA 6 mg/kg,
ip., LV 90 mg/kg, ip.; 5-FU 50 mg/kg, ip.; weekly for 2 weeks); Group 4
(G4), TEM + PAZ + FOLFOX (TEM 25 mg/kg, oral.; PAZ 50 mg/kg,
oral, daily for 3 weeks; OXA 6 mg/kg, ip., LV 90 mg/kg, ip.; 5-FU 50
mg/kg, ip.; weekly for 2 weeks) (Figure 1B). Tumor length, width and
mouse body weight was measured once per week. Tumor volume was cal-
culated with the following formula: Tumor volume (mm3) = length (mm)
× width (mm) × width (mm)/2. Data are presented as mean ± standard
deviation (SD). Mice were imaged with the FluorVivo imaging system
(INDEC Bio Systems, Santa Cruz, CA, USA.) [45].
Hematoxylin and Eosin (H&E) Staining
Before sectioning and staining, fresh tumor samples were fixed in 10%
formalin and embedded in paraffin. Tumor tissue sections (4 μm) slices
were deparaffinized in xylene and rehydrated in an ethanol series. Hema-
toxylin and eosin (H&E) staining was performed according to a standard2protocol. Histological observation and imaging was carried out with a
BHS microscope system (Olympus Corporation, Tokyo, Japan) and images
were analyzed with INFINITY ANALYZE software (Lumenera Corporation,
Ottawa, Canada) [46].
Immunohistochemistry (IHC) and Evaluation
4-μm-thick serial sections were deparaffinized in xylene and rehydrated
in ethanol series. Antigen retrieval was performed by heating in sodium cit-
rate (pH 6.0) and then blocked by non-specific antigen. Thereafter, primary
rabbit polyclonal anti-mouse LYVE-1antibody (1:400, Abcam, Cambridge,
MA, USA) was incubated with slices overnight in a humidified box at 4
°C, followed by incubation with biotinylated goat anti-polyvalent. Sections
were incubated with streptavidin peroxidase for 10 min in DAB for 1–8
min, and in hematoxylin for 2 min. All steps were performed in accordance
with the protocol of a rabbit specific HRP/DAB (ABC) detection IHC kit
(Abcam, Cambridge, MA, USA) at room temperature. Lymphatic vessels
counting was carried out as previously descried [47]. Specimens were im-
aged with a BHS system microscope Images were analyzed with INFINITY
ANALYZE software (Lumenera Corporation, Ottawa, Canada).
Statistical Analysis
All statistical analyses were performed using GraphPad Prism 5 soft-
ware (GraphPad Software, Inc. La Jolla, CA, USA). The one-way analysis
of variance (ANOVA) with Tukey's post hoc test was used when more
than two groups were compared. The paired t-test was used for the para-
metric test to compare the means between two related groups. The data
Figure 3. Effect of drugs on mouse body weight. Bar graph shows body weight in
each group at pre-treatment and post-treatment. n = 5 mice/group. *P< .05.
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sidered statistically significant.
Results
Drug Efficacy on the Colorectal Cancer PDOX
At the endpoint of treatment, the tumor volumes were: G1, untreated
control, 540 ± 110.5 mm3; G2, TEM + PAZ, 293.8 ± 17.8 mm3; G3,
FOLFOX, 268.6 ± 46.2 mm3; G4, TEM + PAZ + FOLFOX, 102.8 ± 11.1
mm3. The untreated control group (G1) tumors grew approximately 5
times larger compared to initiation of treatment. In the TEM + PAZ (G2)
and FOLFOX groups, at the end point, there was a significant inhibition in
tumor growth compared to the control group (P < 0.001). The TEM
+ PAZ + FOLFOX combination group (G4) significantly regressed tumor
growth compared to the control group P < 0.001) (Figure 2). The TEM
+ PAZ + FOLFOX group (G4) had a greater inhibition of tumor growth
than the TEM + PAZ group (G2) or FOLFOX group (G3) (P <0.01)
(Figure 2).
Effect of Treatment on Body Weight
To determine whether the drug treatments had an effect on body
weight, we measured the mouse body weight pre-treatment and post-
treatment. Final body weight of mice in the untreated control group in-
creased compared to the initial body weight (P < 0.05) (Figure 3). Mice
treated with TEM + PAZ + FOLFOX also decreased their body weight
compared to the initial body weight (P< 0.05) (Figure 3). There was no
significant difference in body weight among the TEM + PAZ and
FOLFOX groups (Figure 3). There were no animal deaths in any group.
Tumor Histology Analysis Colorectal Cancer PDOX
Histologically, the control group tumor mainly comprised viable cancer
cells (Figure 4A). In the tumors treated with FOLFOX, the cancer-cell den-
sity was lower than the TEM+PAZ group (Figure 4, B and C). In all treated
groups (G2, G3 and G4), cancer-cell density was lower than the control
(Figure 4, B–D). The strongest reduction in cancer cell density was observedFigure 2. Imaging PDOX tumors treated with each drug, and quantitative efficacy of ch
mouse models from each group at the endpoint. Arrows indicate GFP-expressing tumor
with FOLFOX; G4: treated with TEM + PAZ + FOLFOX. The FluorVivo imaging System
each time point to volume at initiation of treatment) for each drug and control group. n
3when colorectal cancer PDOX tumors were treated with the combination of
TEM+ PAZ+ FOLFOX (Figure 4D).
PAZ Inhibited the Lymphatic Vessel Density (LVD) and Lymphangiogenesis in the
Colorectal Cancer PDOX Mouse Model
The lymphatic vessel density (LVD) and lymphangiogenesis of colorec-
tal cancer PDOX tumors weremarked by LYVE-1 antibodies using immuno-
histochemical staining. Tumors treatedwith PAZ inG2 andG4 groups had a
significantly lower lymphatic vessel density (LVD) compared to groups G1
and G3 (P<0.01) (Figure 5). These results suggest that PAZ could inhibit
lymphangiogenesis of colorectal cancer in a PODX mouse model.
Discussion
Although FOLFOX is first-line treatment for colorectal cancer, there
is still recurrence and metastasis of tumors due to resistance to OXA or
5-FU [48] . Several studies showed that TEM [49, 50] and PAZ [30,emotherapy on the colorectal cancer PDOX model. Images of representative PDOX
stromal cells. (A) G1: untreated control; G2: treated with TEM+ PAZ; G3: treated
was used. (B) Line graphs indicate relative tumor volume (ratio tumor volume at
= 5 mice/group. **P< 0.01; ***P< 0.001.
Figure 4. Histology of colorectal cancer PDOX mouse model in treated and untreated tumors. Hematoxylin and eosin (H&E)-stained sections of the (A) Untreated control
group. (B) TEM+ PAZ-treated group. (C) FOLFOX-treated group, and (D) TEM+ PAZ + FOLFOX-treated group. Microscope magnification 200×.
G. Zhu et al. Translational Oncology 13 (2020) 10073931] could effectively inhibit the progression of colorectal cancer. In the
present study, we found that TEM and PAZ combined with FOLFOX can
regress a colorectal cancer in a PDOX mouse model. This is the firstFigure 5. PAZ inhibits lymphangiogenesis of a colorectal cancer PDOXmousemodel. (A)
(LYVE-1) in the control group. (B) Lymphatic vessels stained in TEM+ PAZ group. (C)
+ PAZ + FOLFOX group. (E) Bars with LYVE-1 lymphatic vessel staining density. Arro
4study which shows that the TEM + PAZ + FOLFOX combination is ef-
fective in colorectal cancer using a colorectal cancer PDOX mouse
model.Representative lymphatic vessel stainedwith endothelial hyaluronic acid receptor 1
Lymphatic vessels stained in FOLFOX group. (D) Lymphatic vessels stained in TEM
ws indicate lymphatic vessels. Magnification 200×. **P<0.01.
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with bioavailability almost 100%. TEMhas been approved for glioblastoma
[51, 52], sarcoma [53, 54] as well as melanoma [35]. We previously re-
ported that TEMwas effective in PDOXmouse models of sarcoma and mel-
anoma [40, 55–65].
We previously also reported that PAZ was effective in PDOX model of
sarcomas [46, 61–63]. PAZ has a high affinity with VEGFR-1/2/3, which
can inhibit the signaling pathway induced by VEGFRs and regulate corre-
sponding physiological functions [25]. We found that the LYVE-1 staining
was reduced in the G2 and G4 groups compared to the G1 and G3 groups,
suggesting that PAZ could inhibit the lymphangiogenesis.
Our results suggest that the TEM + PAZ + FOLFOX combination has
clinical potential for patient with colorectal cancer and also show the im-
portance of PDOX models for individualized therapy. The detection of the
PDOX model was increased by initial growth of the tumor in transgenic
nude mice expression a fluorescent protein [42–44].
The reduction in lymphangiogenesis and no death in the treated groups
suggest that the combination of TEM+ PAZ + FOLFOX is superior. How-
ever, we have not tested the survival within the treated groups. However,
based on the final tumor volume, high efficacy is very clear in that combi-
nation of TEM + PAZ + FOLFOX regressed the tumor. Survival studies
will be done in future experiments.
Conclusions
Our results together suggest that TEM+ PAZ+ FOLFOX combination
is a novel effective treatment for colorectal cancer in a PDOXmouse model.
We also found that therapy regimen including PAZ could inhibit
lymphangiogenesis in the colorectal cancer PDOX mouse model.
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